Authors' reply to Foster and colleagues

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Koretz, Ronald L ^a   Lin, Kenneth W ^b   Ioannidis, John P A ^c   Lenzer, Jeanne ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; DRUG EFFICACY; END STAGE LIVER DISEASE; FIBROSIS; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIFESTYLE MODIFICATION; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TREATMENT RESPONSE; MASS SCREENING; PROCEDURES;

HEPATITIS C; HUMANS; MASS SCREENING;

EID: 84924133765     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1000     Document Type: Letter

References (6)

1. Foster GR, Gore C, Hudson M., Moss P, Ustianowski A, Ryder S., et al Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified. BMJ 2015;350:h998.
2. Koretz RL, Lin KW, Ioannidis JPA, Lenzer J. Is widespread screening for hepatitis C justified? BMJ 2015;350:g7809. (13 January.)
3. Van der Meer AJ. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015;64:364-6.
4. Kraus MR, Schafer A, Teuber G., Porst H, Sprinzl K, Wollschlager S., et al Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology 2013;58:497-504.
5. Poynard T, McHutchison J, Manns M., Trepo C, Lindsay K, Goodman Z., et al Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
6. Van der Meer A, Feld J, Hofer H, Almasio PL, Calvaruso V, Fernandez-Rodriguez CM, et al. The risk for hepatocellular carcinoma among patients with chronic HCV infection and advanced hepatic fibrosis following sustained virological response: Abstract 143. 64th annual meeting of the American Association for the Study of Liver Diseases, Washington, DC, 2013.